Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 207-213 , May 2007

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial

  • Chia-Chi Lin, M.D., Ph.D.

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Chih-Hung Hsu, M.D., Ph.D.

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Tzyh-Chyuan Hour, Ph.D.

      Affiliations

    • Institute of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan
    • ,
  • Ann-Lii Cheng, M.D., Ph.D.

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chao-Yuan Huang, M.D.

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Kuo-How Huang, M.D.

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Jun Chen, M.D.

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yeong-Shiau Pu, M.D., Ph.D.

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.:+1-886-2-23123456 ext 5249; fax: +1-886-2-23219145.

Received 13 February 2006 ,Revised 31 May 2006 ,Accepted 1 June 2006.

References 

  1. Joly F, Tannock IF. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol. 2004;15:1582–1584
  2. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  3. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol. 1999;17:2506–2513
  4. Osoba D, Tannock IF, Ernst DS, et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654–1663
  5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  6. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  7. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate (A phase II trial of the Eastern Cooperative Oncology Group). Cancer. 1993;72:2457–2460
  8. Esteban E, Gonzalez de Sande L, Fernandez Y, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol. 2003;14:1640–1647
  9. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol. 2004;22:512
  10. Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion of paclitaxel (Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma). Cancer. 2000;89:431–436
  11. Huan SD, Aitken SE, Stewart DJ. 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: A phase II study. Ann Oncol. 1994;5:644–645
  12. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate (Advanced Colorectal Cancer Meta-Analysis Project). J Clin Oncol. 1992;10:896–903
  13. Ardalan B, Chua L, Tian EM, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol. 1991;9:625–630
  14. Lin CC, Hsu CH, Chen J, et al. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res. 2001;21:1385–1390
  15. Droz JP, Muracciole X, Mottet N, et al. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003;14:1291–1298
  16. Pu YS, Chen J, Huang CY, et al. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. J Urol. 2001;166:2082–2085
  17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55
  18. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol. 1999;17:3461–3467
  19. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  20. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain. 1975;1:277–299
  21. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–1468
  22. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191–192
  23. Verbel DA, Kelly WK, Smaletz O, et al. Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial. Urology. 2003;61:142–144
  24. Holmes FA, Madden T, Newman RA, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996;14:2713–2721
  25. Grem JL, Nguyen D, Monahan BP, et al. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol. 1999;58:477–486
  26. Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999;17:1664–1671
  27. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44–53
  28. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol. 2001;19:2509–2516
  29. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003;98:2592–2598
  30. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343–3351

PII: S1078-1439(06)00149-9

doi: 10.1016/j.urolonc.2006.06.002

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 207-213 , May 2007

Article Tools

* Image Usage & Resolution